Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheryl Baxter

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Public Health|May 31, 2026
Global inequities in hepatitis B and C genomic surveillance revealed through an interactive data integration dashboardDerek Tshiabuila, Vagner Fonseca, Danilo de Castro Silva, et al.
The New England Journal of Medicine|February 26, 2010
Timing of initiation of antiretroviral drugs during tuberculosis therapySalim S Abdool Karim, Kogieleum Naidoo, Anneke Grobler, et al.
BMJ Open|January 7, 2022
CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in womenTanuja Narayansamy Gengiah, Quarraisha Abdool Karim, Ishana Harkoo, et al.
The New England Journal of Medicine|October 21, 2011
Integration of antiretroviral therapy with tuberculosis treatmentSalim S Abdool Karim, Kogieleum Naidoo, Anneke Grobler, et al.
Trials|December 21, 2014
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trialLeila E Mansoor, Quarraisha Abdool Karim, Kathryn T Mngadi, et al.
Nature Communications|November 21, 2019
HPV infection and the genital cytokine milieu in women at high risk of HIV acquisitionLenine J P Liebenberg, Lyle R McKinnon, Nonhlanhla Yende-Zuma, et al.
BMC Infectious Diseases|July 29, 2024
HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in MozambiqueNália Ismael, Hernane Gemusse, Isabel Mahumane, et al.
Trials|March 10, 2011
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trialQuarraisha Abdool Karim, Ayesha Bm Kharsany, Janet A Frohlich, et al.
Science (New York, N.Y.)|July 21, 2010
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenQuarraisha Abdool Karim, Salim S Abdool Karim, Janet A Frohlich, et al.
BMC Genomics|October 14, 2025
Genomic diversity and surveillance of SARS-CoV-2 in NigeriaThomas J Y Kono, Ezenwa J Onyemata, Natalia Blanco, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Public Health|May 31, 2026
Global inequities in hepatitis B and C genomic surveillance revealed through an interactive data integration dashboardDerek Tshiabuila, Vagner Fonseca, Danilo de Castro Silva, et al.
The New England Journal of Medicine|February 26, 2010
Timing of initiation of antiretroviral drugs during tuberculosis therapySalim S Abdool Karim, Kogieleum Naidoo, Anneke Grobler, et al.
BMJ Open|January 7, 2022
CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in womenTanuja Narayansamy Gengiah, Quarraisha Abdool Karim, Ishana Harkoo, et al.
The New England Journal of Medicine|October 21, 2011
Integration of antiretroviral therapy with tuberculosis treatmentSalim S Abdool Karim, Kogieleum Naidoo, Anneke Grobler, et al.
Trials|December 21, 2014
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trialLeila E Mansoor, Quarraisha Abdool Karim, Kathryn T Mngadi, et al.
Nature Communications|November 21, 2019
HPV infection and the genital cytokine milieu in women at high risk of HIV acquisitionLenine J P Liebenberg, Lyle R McKinnon, Nonhlanhla Yende-Zuma, et al.
BMC Infectious Diseases|July 29, 2024
HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in MozambiqueNália Ismael, Hernane Gemusse, Isabel Mahumane, et al.
Trials|March 10, 2011
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trialQuarraisha Abdool Karim, Ayesha Bm Kharsany, Janet A Frohlich, et al.
Science (New York, N.Y.)|July 21, 2010
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenQuarraisha Abdool Karim, Salim S Abdool Karim, Janet A Frohlich, et al.
BMC Genomics|October 14, 2025
Genomic diversity and surveillance of SARS-CoV-2 in NigeriaThomas J Y Kono, Ezenwa J Onyemata, Natalia Blanco, et al.
Pageof 11